Federal prosecutors like cases that are easy or will win political points. There is no public outrage against unicorn biotech companies to cash in on, and it doesn't seem like there is a slam dunk fraud case either.
This is a better way of saying what I stated in my first paragraph, and, really, a better way of saying my whole comment if you don't care to see the details of my conclusion.